Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin

Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.